BioSpace News Archive

Todos Medical, Ltd., a comprehensive medical diagnostics and related solutions company, announced that its President & CEO Gerald Commissiong will be presenting at the RHK 2022 Disruptive Growth Conference on Tuesday, December 6th at 12:20pm ET.

Burke Porter Group (BPG) today announced the acquisition of Quantum 3 (Q3).

On Friday, November 11, 2022, spine surgeon Jeffrey R. Carlson, MD, of Orthopaedic & Spine Center, performed the first implant of the Align Peek T/PLIF Intervertebral cage at Mercy Bon Secours Mary Immaculate Hospital in Newport News, Va.

Vision Care Group and ThinkCyte today announced a research partnership aimed at advancing cell therapy in retinal disease.

Pumas-AI, a science-first organization that turns data into life-saving decisions faster, announced today has hired Dr. Salim Bouchene as Senior Scientist, based in France.

New View Surgical, an emerging medical device company developing proprietary imaging and access technologies for minimally invasive surgery, announced the first-in-human procedure utilizing the VisionPort™ System.

Novartis today announced results from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2−) metastatic breast cancer (MBC), including patients with visceral crisis.

Eli Lilly and Company (NYSE: LLY) today announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio® (abemaciclib) in combination with standard endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC).

A clinical study conducted with participation by Florida Cancer Specialists & Research Institute, LLC (FCS) has led to FDA approval of a new immunotherapy that improves chemotherapy treatment outcomes for patients with metastatic non small-cell lung cancer (mNSCLC).

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced topline results from Part 2 (repeat-dose portion) of the Phase 1 study of RT-102, the RaniPill™ GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being developed for the treatment of osteoporosis.